[go: up one dir, main page]

WO2000023568A3 - Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells - Google Patents

Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells Download PDF

Info

Publication number
WO2000023568A3
WO2000023568A3 PCT/US1999/015734 US9915734W WO0023568A3 WO 2000023568 A3 WO2000023568 A3 WO 2000023568A3 US 9915734 W US9915734 W US 9915734W WO 0023568 A3 WO0023568 A3 WO 0023568A3
Authority
WO
WIPO (PCT)
Prior art keywords
overproduction
compositions
cells
methods
oxygen species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015734
Other languages
French (fr)
Other versions
WO2000023568A2 (en
Inventor
Michael Brownlee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2000023568A2 publication Critical patent/WO2000023568A2/en
Publication of WO2000023568A3 publication Critical patent/WO2000023568A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Ecology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The subject invention provides means of identifying agents identified as capable of reducing levels of ROS or ROS level correlated indicators such as levels of LPs, AGEs, NFλB, PKC, or aldose reductase activation in insulin-independent cells grown under high glucose conditions.
PCT/US1999/015734 1998-10-06 1999-07-12 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells Ceased WO2000023568A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16718298A 1998-10-06 1998-10-06
US09/167,182 1998-10-06
US30568899A 1999-05-04 1999-05-04
US09/305,688 1999-05-04

Publications (2)

Publication Number Publication Date
WO2000023568A2 WO2000023568A2 (en) 2000-04-27
WO2000023568A3 true WO2000023568A3 (en) 2000-09-14

Family

ID=26862926

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/015734 Ceased WO2000023568A2 (en) 1998-10-06 1999-07-12 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
PCT/US1999/023457 Ceased WO2000019993A2 (en) 1998-10-06 1999-10-06 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023457 Ceased WO2000019993A2 (en) 1998-10-06 1999-10-06 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells

Country Status (2)

Country Link
AU (1) AU6421899A (en)
WO (2) WO2000023568A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
IL144503A0 (en) 1999-01-25 2002-05-23 Nat Jewish Med & Res Center Substituted porphyrins
FR2806911B1 (en) * 2000-03-28 2003-01-10 Univ Rene Descartes USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR DEFICIENCIES
AU2002312194B8 (en) 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
WO2003052067A2 (en) * 2001-12-13 2003-06-26 University Of Virginia Patent Foundation Vector mediated organelle transfection
PT1463563E (en) 2001-12-14 2009-03-19 Alcon Inc Superoxide dismutase mimics for the treatment of ocular disorders and diseases
MXPA05005937A (en) * 2002-12-06 2005-08-18 Alcon Inc Histone deacetylase inhibitors for treating degenerative diseases of the eye.
EP2418281B1 (en) 2003-10-24 2016-06-01 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
CN1889961A (en) 2003-12-11 2007-01-03 爱尔康公司 Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
US20080015144A1 (en) * 2003-12-12 2008-01-17 Alvert Einstein College Of Medicine Of Yeshiva Uni Glp- (9-36) Methods and Compositions
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2008044138A1 (en) * 2006-10-12 2008-04-17 Syddansk Universitet Optical nanosensor for detection of reactive oxygen species
ES2375023T3 (en) 2008-02-29 2012-02-24 Buck-Chemie Gmbh ADHESIVE AGENT FOR APPLICATION ON A HEALTH OBJECT.
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
JP5608644B2 (en) 2008-05-23 2014-10-15 ナショナル ジューイッシュ ヘルス Methods for treating damage associated with exposure to alkylated species
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
EP2911662A4 (en) * 2012-10-25 2016-09-28 Technion Res & Dev Foundation Method of treatment of disease
AU2017357076A1 (en) * 2016-11-14 2019-05-30 Cornell University Methods for drug discovery using stem cell-derived schwann cells
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (en) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd Preventive and therapeutic agent for diabetic complication
WO1998027426A1 (en) * 1996-12-17 1998-06-25 University Of Aberdeen Channel mediating substrates
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
WO1996009053A1 (en) * 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
CA2224088A1 (en) * 1995-06-07 1996-12-19 Monsanto Company Process for preparing substituted polyazamacrocycles
ATE238307T1 (en) * 1997-11-03 2003-05-15 Univ Duke SUBSTITUTED PORPHYRINS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (en) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd Preventive and therapeutic agent for diabetic complication
WO1998027426A1 (en) * 1996-12-17 1998-06-25 University Of Aberdeen Channel mediating substrates
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CURCIO, F. AND CERIELLO, A.: "Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications.", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, vol. 28A, no. 11-12, November 1992 (1992-11-01) - December 1992 (1992-12-01), pages 787 - 790, XP000879178 *
DATABASE WPI Section Ch Week 199308, Derwent World Patents Index; Class B05, AN 1993-061598[08], XP002131312, "New drug for preventing and treating diabetic complications comprises 1,4-benzoquinone or its hydroquinone form; treats nephropathy, neuropathy, arteriosclerosis etc." *
ELLIS, E.A. ET AL.: "Increased NADH oxidase activity in the retina of the BBZ/WOR diabetic rat", FREE RADICAL BIOLOGY AND MEDICINE, vol. 24, no. 1, 1 January 1998 (1998-01-01), pages 111 - 120, XP000879172 *
GIARDINO, I. ET AL.: "BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells.", JOURNAL OF CLINICAL INVESTIGATION, vol. 97, no. 6, March 1996 (1996-03-01), pages 1422 - 1428, XP000879169 *
KING, G.L. AND BROWNLE, M.: "The cellualr and molecular mechanisms of diabetic complications", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 25, no. 2, June 1996 (1996-06-01), pages 255 - 270, XP000878790 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins

Also Published As

Publication number Publication date
AU6421899A (en) 2000-04-26
WO2000019993A3 (en) 2001-03-01
WO2000019993A2 (en) 2000-04-13
WO2000023568A2 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
WO2000023568A3 (en) Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
WO2002090539A3 (en) Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
EP2266396A3 (en) Modulation of stem cells using zinc finger proteins
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
CA2222680A1 (en) Endoparasiticidal agents
ZA200006576B (en) Methods and compositions for expression of transgenes in plants.
AU2002233225A1 (en) Bioanalytical reagent, method for production thereof, sensor platforms and detection methods based on use of said bioanalytical reagent
AU2889201A (en) Automatic water toxicity measuring apparatus
WO2005000229A3 (en) Compositions and methods for modulating s-nitrosoglutathione reductase
WO2002008461A3 (en) A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
MXPA01011182A (en) Methods, compositions and kits for biological indicator of sterilization.
WO2001096604A3 (en) Assay for genetic polymorphisms using scattered light detectable labels
AU2001249444A1 (en) Methods and compositions for the simultaneous detection of multiple analytes
AU2002241873A1 (en) Whitening compositions containing ascomycete derived enzyme
AU2002242858A1 (en) Patch-clamping and its use in analysing subcellular features
WO2000075363A3 (en) Enzymatic measurement of mycophenolic acid
HK1039965A1 (en) Methods and kits for detection of cryptosporidium parvum
WO2001066144A3 (en) Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
AU2001266274A1 (en) Assay techniques based on growth stage dependent expression inc. elegans
WO2004009843A3 (en) Detection of microorganisms
DE60041198D1 (en) ANTIMICROBIAL COMPOSITIONS
AU3315200A (en) 1,5-anhydro-d-fructose substituted with a hydrophobic group for use as anti-oxidant and/or emulsifier
AU2001261513A1 (en) Composition and method for increasing testosterone levels
WO2002101090A3 (en) Method for determining the existence of animal or vegetable mixtures in organic substrates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase